Medical management of ventricular tachycardia
Reading File
Finding Sources
Finding Sources
Searching PubMed
"ventricular tachycardia" AND treatment
Searching the Web
2025 ventricular tachycardia management guideline stable unstable ACLS amiodarone procainamide
Reading File
Reading File
Reading Web Page
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001376
Reading File
Reading File
Medical management of ventricular tachycardia (VT)
Treat a wide-complex tachycardia as VT unless there is strong evidence otherwise. Management depends first on whether there is a pulse and whether the patient is haemodynamically stable.
1. Pulseless VT
Treat as a shockable cardiac arrest rhythm.
- Immediate defibrillation and high-quality CPR.
- Epinephrine 1 mg IV/IO every 3-5 minutes.
- For VT/VF refractory to defibrillation:
- Amiodarone 300 mg IV/IO bolus, then 150 mg once if needed, or
- Lidocaine 1-1.5 mg/kg IV/IO, with additional 0.5-0.75 mg/kg doses to a maximum of 3 mg/kg.
- Correct reversible causes: hypoxia, acidosis, hypo/hyperkalaemia, hypomagnesaemia, acute coronary occlusion, tamponade, pulmonary embolism, toxins, etc.
This is an emergency requiring the adult cardiac-arrest algorithm. The AHA adult advanced life support guideline advises immediate defibrillation for polymorphic VT because it cannot be reliably synchronized.
2. VT with a pulse but haemodynamic instability
Instability includes hypotension, shock, altered mental status, ischemic chest discomfort, acute pulmonary edema, or heart failure.
- Immediate synchronized cardioversion.
- Give analgesia/sedation if feasible, but do not delay cardioversion.
- If the rhythm is polymorphic or synchronization is not possible, use unsynchronized defibrillation.
- Start an antiarrhythmic infusion after successful cardioversion when recurrence risk is high, usually amiodarone.
Textbook guidance: a pulsed VT causing compromise requires electrical cardioversion, while a stable VT may initially receive drug therapy. Tintinalli's Emergency Medicine, p. 157.
3. Haemodynamically stable sustained monomorphic VT
Establish monitoring, IV access, 12-lead ECG, and obtain expert cardiology input. Use one antiarrhythmic infusion while preparing for immediate cardioversion if the patient deteriorates.
| Drug | Typical IV regimen | Important cautions |
|---|---|---|
| Procainamide | 20-50 mg/min IV until VT ends, hypotension occurs, QRS widens >50%, or max 17 mg/kg; then 1-4 mg/min infusion | Avoid in prolonged QT, heart failure, or severe LV dysfunction; may cause hypotension |
| Amiodarone | 150 mg IV over 10 min; may repeat if VT recurs; then 1 mg/min for 6 h, followed by 0.5 mg/min | Can cause hypotension and bradycardia; watch QT interval |
| Sotalol | 100 mg, about 1.5 mg/kg, IV over 5 min | Avoid with prolonged QT, renal impairment, or heart failure |
| Lidocaine | 1-1.5 mg/kg IV, then infusion usually 1-4 mg/min | Often useful in ischemia-related VT or when amiodarone is unsuitable |
Procainamide has shown better acute conversion efficacy than amiodarone or lidocaine in stable VT, but its infusion must be slow because rapid administration can produce hypotension. Tintinalli's Emergency Medicine, p. 157.
Do not use verapamil or diltiazem for an undifferentiated wide-complex tachycardia, as this may cause severe deterioration if the rhythm is VT.
4. Polymorphic VT and torsades de pointes
Polymorphic VT is treated as unstable: immediate defibrillation if sustained or causing compromise.
If there is torsades de pointes with prolonged QT:
- Stop QT-prolonging drugs.
- Give magnesium sulfate 2 g IV, even if serum magnesium is normal.
- Correct potassium toward the high-normal range and correct other electrolytes.
- Treat bradycardia or pauses with overdrive pacing; isoproterenol may be used for acquired pause-dependent torsades under specialist direction.
- Avoid QT-prolonging antiarrhythmics, particularly sotalol and procainamide.
Magnesium is particularly indicated for hypomagnesaemia, QT prolongation, polymorphic VT, and torsades; pacing can prevent recurrent pause-dependent torsades until the cause is corrected. Tintinalli's Emergency Medicine, p. 157.
5. Address the trigger and prevent recurrence
After acute termination, identify and treat the substrate:
- Acute coronary syndrome or myocardial ischemia: urgent reperfusion evaluation.
- Correct hypoxia, acid-base disturbance, potassium or magnesium abnormalities.
- Stop proarrhythmic or QT-prolonging medications and address toxicity.
- Evaluate structural heart disease with echocardiography and, where appropriate, cardiac MRI or coronary assessment.
- Beta-blockers are important in many patients with ischemic cardiomyopathy or catecholamine-driven VT.
- For recurrent sustained VT, especially with structural heart disease:
- ICD for secondary prevention when indicated.
- Amiodarone or sotalol can reduce recurrent episodes and ICD shocks but do not replace an indicated ICD.
- Refer for electrophysiology assessment and catheter ablation for recurrent VT, VT storm, or drug-refractory/intolerant VT.
Recent reviews support an increasing role for catheter ablation in selected structural-heart-disease VT, but acute unstable VT still requires immediate electrical treatment (PMID 39122752).
This is a shared conversation. Sign in to Orris to start your own chat.